Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease.
J Pediatr
; 214: 227-230, 2019 11.
Article
em En
| MEDLINE
| ID: mdl-31351682
Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoglobulinas Intravenosas
/
Síndrome de Linfonodos Mucocutâneos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Aspecto:
Patient_preference
Limite:
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Pediatr
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Japão
País de publicação:
Estados Unidos